ACUTE LEUKEMIAS XVII
Biology and Treatment Strategies

Munich, Germany - February 24-27, 2019

International Symposium

Selected Abstracts Acute Leukemias XV for Poster Presentation

POSTERS

Poster Viewing:
Monday, February 23, 2015: 13.00 – 18.00
Tuesday, February 24, 2015: 09.00 – 18.00

Poster Presentation and Discussion Session:
Monday,  February 23, 2015: 16.15 – 18.00 (MSV)

Prize Giving Ceremony: 3 of Best Free Contributions:
Tuesday, February 24, 2015: 16.30 – 17.30 (MSIX)


I. LEUKEMIC STEM CELLS

(1) Clonal Variegation and Dynamic Competition of Leukemia-Initiating Cells in Infant Acute Lymphoblastic Leukemia with MLL Rearrangement
M. Bardini, P. Woll, C. Corral et al.

(2) Towards New Clinical Hypothesis Using a Mathematical Model of Acute Leukemias
D. Görlich and J. Banck

(3) The Impact of Chromosome 17p Deletion on Tumorigenesis and Therapy Response
Yu Liu, Chong Chen, and S. Lowe

(4) Leukemia Initiating Cells in Acute Lymphoblastic Leukemia Are Characterized by Low Cellular Energy Metabolism
L.H. Meyer, L. Trentin, M. Queudeville et al.

(5) GPR56 Identifies the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia
C. Pabst, A. Bergeron, V. Lavallée et al.

(6) Cell of Arrest of Cancer: Functional Impact and Genetic Determinism in Acute Myeloid Leukemia
F. Vergez, S. Bertoli, M. Bousquet et al.

(7) Whole EXOME Sequencing in Single Cells from Pediatric Patients with Acute Myeloid Leukemia and NPM1/FLT3 Mutations
C. Walter, W. Hofmann, K. Reinhardt et al.


II. AML – BIOLOGY

(8) IDH Mutation Deregulates LYN Kinase and Uncovers a Synergistic Clinically Achievable Response with ATRA and DASATINIB
H. Boutzen, E. Saland, F. de Toni et al.

(9) Overweight is an Independent Adverse Prognostic Factor in Acute Myeloid Leukemia (aml) in Younger Patients
S. Capovilla, T. Herold, C. Sauerland et al.

(10) In-depth Global DNA Methylation Analysis Reveals an Extreme CPG Island Hypermethylator Pheno-Type
C. Gebhard, L. Schwarzfischer, D. Glatz et al.

(11) Myelodysplastic Syndromes in Ukrainian Chernobyl Clean-Up Workers
D.F. Gluzman, L.M. Sklyarenko, S.V. Koval et al.

(12) The Histone Methyltransferase EZH2 Controls Drug Resistance in Acute Myeloid Leukemia (AML)
S. Göllner, S. Agrawal-Singh, T. Schenk et al.

(13) DNMT3A Gene: Distribution of the Mutations and their Stability during Treatment in Patients with AML
I. Jeziskova, M. Musilova, M. Culen et al.

(14) Identification of Novel NUP98-NSD1 Fusion Transcripts in Adult DE NOVO Acute Myeloid Leukemia Patients with t(5;11) (q35;p15.4)
J. Kivioja, J. Lopez Marti, M. Kontro et al.

(15) BCL2 Inhibitors Target Diagnosed and Relapsed AML
M. Kontro, M.M. Majumder, T. Pemovska et al.

(16) Microenvironmental Hypoxia Induces Prognostically Relevant IL-8 in Blasts of Acute Myeloid Leukemia
A. Kütt, M. Wagner, H. Drolle et al.

(17) Development of Nested Multiplex PCR for Simultaneous Detection of Multiple Genetic Alterations in Acute Leukemia
A. Kustanovich, A. Valochnik, and O. Aleinikova

(18) Proteasome Inhibitors Induce FLT3-ITD Degradation through Autophagy in AML Cells
C. Larrue, E. Saland, H. Boutzen et al.

(19) Activation of TRK Receptors in Murine Hematopoietic Stem / Progenitor Cells Induced Acute Leukemia and Mastocytosis
Zh. Li, M. Yang, K. Huang et al.

(20) ASXL1 Mutations Associated with Cytogenetic Findings in de novo and Secondary Acute Myeloid Leukemia
K.N. Manola, K. Kakosaiou, A. Daraki et al.

(21) The Role of STAT5 in FLT3-Mediated Leukemogenesis
T.A. Müller, R. Grundler, R. Istvanffy et al.

(22) Prevalence of PML/RARΑ, AML1/ETO, CBFΒ/MYH11 Translocations and Expression Level of Myeloid CD Markers amongst AML Patients of Assam, India
S. Nath, J. Bhattarcharyya, and K.K. Saikia

(23) The Mutatome of CBFB/MYH11 Rearranged Acute Myeloid Leukemia (AML)
S. Opatz, K.H. Metzeler, T. Herold et al.

(24) A Leukemia Associated CD34/CD123/ CD25/CD99-Positive Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
T. Ottone, D.F. Angelini, G. Guerrera et al.

(25) Leukemic Bone Marrow Cells Derived Microvesicles Increase MicroRNA21 Expression in Umbilical Cord Blood Hematopoietic Stem Cells (IN VITRO)
F. Razmkhah, M. Soleimani, D. Mehrabani et al.

(26) Visualization of AML-Specific FLT3 Mutants and Differential Downstream Signaling
K. Reiter,  A. Meiser, H. Polzer et al.

(27) Hypoxia Regulates FLT3 Expression and Function in Patient Samples and in the BA/F3 Model
S. Sironi, M. Wagner, J. Vasold et al.

(28) Systems Biology of Mixed Lineage Leukemia
R. Slany, M.P. Garcia-Cuellar, K. Hetzner et al.

(29) IN VIVO Imaging Facilitates Reliable and Sensitive Monitoring of Preclinical IN VIVO Treatment Trials in the Individualized Xenograft Mouse Model of AML
B. Vick, M. Rothenberg, N. Sandhöfer et al.

(20) Detection of Chromosome 9q Deletion in Acute Myeloid Leukemia (AML) Patients Using Targeted Sequencing Data
S. Vosberg, T. Herold, K.H. Metzeler et al.

(31) Evaluation of DNA Repair Gene Polymorphisms in Acute Myeloid Leukemia
V. Sugunakar, C. Anuradha, G. Manjula et al.

(32) Acute Myeloid Leukemia Preceded by t-MDS after Succesful Treatment of Chronic Lymphocytic Leukemia with FC-R Regimen: Secondary Leukemia? Another Myeloid Neoplasm? - A Case Report
M. Wach, E. Wasik-Szczepanek, M. Cioch et al.

(33) Mimicking the Bone Marrow Niche IN VITRO: Establishment of a 3D Perfusion Culture System for Mesenchymal Stromal Cells
C. Walter, L. Drakhlis, M. Hinrichs et al.

(34) The DNA-Repair Machinery as a Novel Target in a Humanized t(8;21)+ Pre-Leukemia Model with Activated c-KIT
C. Wichmann, L. Chen-Wichmann, and R. Henschler


III. AML – THERAPY

(35) Evaluation of New DNA Methyltransferases Inhibitors in AML
N.M. Cury, F. Fumagalli, F.S. Emery, et al.

(35b) Elimination of Cells from Patients with Different Subtypes of AML by Dual-Targeting Triplebody 33-16-123 (SPM-2)
T. Braciak, F. Oduncu, G.H. Fey et al.

(36) New Therapeutic Targets for MLL+ AML Identified via MLL-AF9 Depletion
K.K. Fleischmann, P. Pagel, I. Schmid et al.

(37) Localized Biliar Myeloid Sarcoma Followed by Acute Myeloid Leukemia Treated with Chemotherapy and Consequent Allogeneic Stem Cell Transplantation: A Case Report
B. Nicolino, S. Aydin, C. Frairia et al.

(38) A Fluorescence In-Situ Hybridization-Based Screen Allows Rapid Detection of Adverse Cytogenetics in Patients (PTS) with Acute Myeloid Leukemia (AML)
N. Sandhöfer, K. Metzeler, P. Kakadia et al.

(39) The Method of Risk-Adapted Therapy Adult Acute Myeloid Leukemia Based on the Monitoring of Minimal Residual Disease by Multicolor Flow Cytometry
A. Uss, I. Lendina, V. Smolnikova et al.

(40) The Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Acute Myeloid Leukemia and its Inhibition Mediates Anti-Leukemic Effects IN VITRO
J. Wellbrock, E. Latuske, J. Köhler et al.


IV. ALL – BIOLOGY

(41) Influence of Submicroscopic Genomic Rearrangements on Gene Expression in T-CELL Large Granular Lymphocyte Leukemia
C. Bude, K. Iżykowska, M. Zawada et al.

(42) Knockdown of XIAP Sensitizes B-ALL Cells towards Chemotherapy in an Innovative, Dual Luciferase IN VIVO Competition Assay
M. Carlet, J. Vergalli, C. Finkenzeller et al.

(43) Clonality-Analysis in BCRABL-Induced Leukemia by Genetic Barcodes
K. Cornils, D. Winkelmann, L. Thielecke et al.

(44) Drug Sensitivity of Patient-Derived ALL Tumor Cells is Impaired by Co-Culture with Feeder Cells Mimicking the IN VIVO Micro-Environment
S. Ebinger, L. Mura, M. Grunert et al.

(45) Single Cell Clones from a Patient with ALL Show different Drug Sensitivity and Growth Behavior in vivo
C. Finkenzeller, M. Carlet, and I. Jeremias
 
(46) PH-like ALL Is Associated with Homogenous Molecular Alterations and Inferior Outcome in Adults
T. Herold, S. Schneider, K. H. Metzeler et al.

(47) myelodysplasia in Adults with Near-Tetraploidy and Lymphoid (ALL) or Ambiguous Lineage (ALAL) Acute Leukemias
P. Lemez, T. Alpermann, M.C. Bene,  et al.

(48) Overcoming Apoptosis Resistance in Acute Lymphoblastic Leukemia in a Preclinical ALL Xenograft Model
L.H. Meyer, M. Schirmer, M. Queudeville et al.

(49) Prognostic Importance of mn1-transcript Levels in Patients with Acute Lymphoblastic Leukemia (ALL) Treated According to the Protocol ALL-MB-2008
N. Migal, I. Pakhomova, I. Emelianova et al.

(50) Incidence of IKZF1 Deletions in Russian Cohort of Pediatric B-Precursor ALL. Results of the Russian Moscow-Berlin Study Group
A. Panfyorova, Yu. Olshanskaya, A. Kazakova et al.

(51) AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct and Selective Fashion
T. Pemovska, E. Johnson, M. Kontro et al.

(52) The Metabolic Stress Sensor MLXIP Mediates Malignancy of cALL IN VIVO
A. Sipol, T.G.P. Grünewald, C.M. Wernicke et al.


V. ALL – THERAPY

(53) International Validation of a Harmonized NGS PGM Assay at Clinical Laboratories in the US and the EU
N. Adams, G. Pawlowsky, Y. Huang et al.

(54) A Phase III Multicenter, Randomized, Study Evaluating Efficacy and Safety of Erythrocyte Encapsulated L-Asparaginase (ERYASP) versus Native L-Asparaginase (L-ASP) in Combination with COOPRALL Regimen in Patients with First Relapse of Acute Lymphoblastic Leukemia (ALL)
Y. Bertrand, X. Thomas, and Y. Godfrin
 
(55) IN VIVO Response to Remission Induction Poly-Chemotherapy Modeled in NOD/SCID Mice Reflects Patient Risk and Outcome
V. Münch, N. Hasan, M. Schirmer et al.

(56) Effective IN VIVO Targeting of BCP-ALL in a NOD/SCID/huALL Mouse Model by CD70 Directed Immunotherapy
Q. Sun, K.-M: Debatin, and L.H. Meyer


VI. APL – THERAPY

(57) Proteasome Activity Is Dispensible for the Degradation of PML-RARA: Efficacy of Bortezomib along with Arsenic Trioxide in the Treatment of ATO Sensitive and Resistant Acute Promyelocytic Leukemia
V. Mathews, S Ganesan, A.A. Alex et al.


VII. PEDIATRIC ACUTE LEUKEMIAS

(58) Single Cell Developmental Classification of B Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL) Reveals Link between Phenotype, Signaling and Drug Response
K.L. Davis, N. Samusik, Z. Good et al.

(59) Primary Induction Failure and Early Relapses in Children with AML
I. Kalinin, M. Maschan, D. Baydildina et al.

(60) GATA1-Centered Genetic Network on Chromosome 21 Drives Down Syndrome Acute Megakaryoblastic Leukemia
J.-H. Klusmann, L. Stachorski, V.R. Thangapandi et al.

(61) Early T Precursor (ETP) Phenotype Impact on Outcome of Pediatric Acute Lymphoblastic Leukemia (ALL)
M. Koehler; J.F. Oliveira; J. Caetano et al.

(62) Monitoring of Asparagine in CSF after Administration of Pegylated E.coli Asparaginase within the AIEOP-BFM ALL 2009 Trial
C. Lanvers-Kaminsky, A. Ballerini, A. Möricke et al.

(63) Outcome of Pediatric Acute Myeloid Leukemia Treated with AML-BFM 98 Protocol in a Developing Country: Lessons and Challenges
V. Mathews, A. Korula, B. George et al.

(64) Loss of Fusion Gene in Leukemia with MLL-Rearrangement Provides Insight to Development of 3-Way-Translocations
M. Hinrichs, C. von Neuhoff, J.Alten et al.

(65) Therapy Adaption in the Genetically High Risk Group in Childhood Acute Myeloid Leukemia: A Report of AML-BFM-Study 2004
C. von Neuhof, M. Rasche, J. Bradtke et al.

(66) Expression of Mecom Transcripts in Childhood Acute Leukemia
I. Pakhomova, A. Kustanovich, A. Valochnik et al.

(67) Tumor Cells’ Immunophenotype Predicts the Presence of MLL Gene Rearrangements in Infant Acute Leukemia
A. Popov, G. Tsaur, T. Verzhbitskaya et al.

(68) New Aspects of Genetic High Risk Stratification in Pediatric AML: A Report of AML-BFM-Study 2004
M. Rasche, C. von Neuhoff, J. Bradtke et al.

(69) Development of Patient-Specific Assay for MRD Detection in Pediatric Patients with CEBPA-Positive NK AML
M. Stsiohantsava and A. Kustanovich

(70) Minimal Residual Disease in Peripheral Blood and Bone Marrow of Infants with MLL-Rearranged Acute Lymphoblastic Leukemia. Concordance and Prognostic Significance
G. Tsaur, A. Popov, T. Riger et al.


VIII. IMMUNOTHERAPY OF ACUTE LEUKEMIAS

(71) Targeting Acute Myeloid Leukemias with TCR-Transgenic T Cells
R. Klar, E. Bräunlein, S.Windeisen et al.

(72) PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody Construct (AMG 330) Mediated Lysis of Primary AML Cells
C. Krupka, P. Kufer, R. Kischel et al.


IX. STEM CELL TRANSPLANTATION

(73) Autologous Hematopoietic Stem Cell Transplantation for Adults with Acute Myeloid Leukemia: A Single-Centre Experience
M. Cioch, M. Wach, D. Jawniak et al.

(74) Haploidentical 2nd Allo-HSCT for Treatment of Acute Leukemia (AL) Relapse after 1st Allo-HSCT: Retrospective Registry Analysis of 63 PTs
M. Christopeit, J. Tischer, M. Bornhäuser et al.

(75) Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Two Reduced-Intensity Regimes
S. Fritsch, N. Engel, W. Hil et al.

(76) New Strategy in Stem Cell Transplantation for AML: CD96 Antibody TH-111 Removes Leukemic Stem Cells from Autografts
M. Gramatzki, M. Staudinger, Ch. Kellner et al.

(77) Monitoring of Bone Marrow Chimerism after Allogeneic HSCT – Early Relapse Detection by a Quantitative PCR Approach
R. Reibke, A. Dick, M. Hubmann et al.